Role for Cysteine Protease Cathepsins in Heart Disease: Focus on Biology and Mechanisms With Clinical Implication

The extracellular matrix (ECM) of the heart is composed largely of elastin and collagen and plays many roles in cardiac wall and valve homeostasis. Maintenance of a healthy cardiac system relies on controlled biosynthesis, maturation, function, and breakdown of ECM proteins. Dysregulation of proteolytic enzymes may disrupt these normal biological processes in myocardium-coronary-valve disease (CCVD). Substantial evidence supports the involvement of matrix metalloproteinase (MMP) and serine protease families in this process (reviewed elsewhere1,2). Cysteinyl proteases have received much less consideration in this regard, even though cardiovascular cells and macrophages with greatly expanded lysosomal compartments figure prominently in the pathogenesis of CCVD. Lysosomal cysteine proteases, generally known as cathepsins, were discovered in the second half of the 20th century. In the initial years after their discovery, cysteinyl cathepsins were shown to localize in lysosomes and endosomes and to function there to degrade unwanted intracellular or endocytosed proteins.3–5 However, the recent recognition of the inducible cathepsins F, K, S, B, and L led to the unraveling of their molecular functions in inflammatory and/or autoimmune diseases such as atherosclerosis,6–11 obesity,12–14 rheumatoid arthritis,15,16 cardiac repair,17 cardiomyopathy,18–20 and cancer.21 Most strikingly, we have now discovered that these cathepsins can be secreted into and function within the extracellular spaces. The observations of cathepsin expression and activity in failing cardiac tissues22–24 and valve tissues25–27 from humans and animals and in cultured media of cardiomyocytes,22,24 cardiac fibroblasts,22 vascular smooth muscle cells,28 endothelial cells,12 and macrophages6,10 have significantly broadened our understanding of their potential roles in cardiovascular pathogenesis. Furthermore, recent studies have shown that pharmacological cathepsin inhibition exhibits cardiovascular protective actions in animal models. …

[1]  P. Libby,et al.  Cathepsin K Deficiency Reduces Elastase Perfusion–Induced Abdominal Aortic Aneurysms in Mice , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  N. Dhalla,et al.  Role of various proteases in cardiac remodeling and progression of heart failure , 2012, Heart Failure Reviews.

[3]  T. Reinheckel,et al.  CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. , 2011, The Journal of clinical investigation.

[4]  G. Shi,et al.  Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases. , 2011, Pharmacology & therapeutics.

[5]  Stephen P O'Brien,et al.  Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling. , 2011, Journal of the American Society of Nephrology : JASN.

[6]  P. Libby,et al.  Molecular imaging of macrophage protease activity in cardiovascular inflammation in vivo , 2011, Thrombosis and Haemostasis.

[7]  K. Okumura,et al.  Angiotensin Type 1 Receptor Blocker Reduces Intimal Neovascularization and Plaque Growth in Apolipoprotein E–Deficient Mice , 2011, Hypertension.

[8]  T. Murohara,et al.  Cystatin C: A Possible Sensitive Marker for Detecting Potential Kidney Injury After Computed Tomography Coronary Angiography , 2011, Journal of computer assisted tomography.

[9]  K. Okumura,et al.  Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin , 2011, Journal of hypertension.

[10]  Chao Xu,et al.  Structural basis for the recognition and cleavage of histone H3 by cathepsin L , 2011, Nature communications.

[11]  S. Manzano-Fernández,et al.  β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. , 2011, Journal of the American College of Cardiology.

[12]  A. Gramolini,et al.  Cathepsin-L contributes to cardiac repair and remodelling post-infarction. , 2011, Cardiovascular research.

[13]  B. Wang,et al.  Cystatin C Deficiency Promotes Epidermal Dysplasia in K14-HPV16 Transgenic Mice , 2010, PloS one.

[14]  K. Clément,et al.  Cathepsins and cystatin C in atherosclerosis and obesity. , 2010, Biochimie.

[15]  T. Reinheckel,et al.  Specialized roles for cysteine cathepsins in health and disease. , 2010, The Journal of clinical investigation.

[16]  Jie Du,et al.  Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a “Western-style diet” by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels , 2010, Acta Pharmacologica Sinica.

[17]  Qin M. Chen,et al.  Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. , 2010, Cardiovascular research.

[18]  K. Okumura,et al.  Exercise Training Stimulates Ischemia-Induced Neovascularization via Phosphatidylinositol 3-Kinase/Akt-Dependent Hypoxia-Induced Factor-1&agr; Reactivation in Mice of Advanced Age , 2010, Circulation.

[19]  J. Li,et al.  Plasma Cathepsin L and Its Related Pro/Antiangiogenic Factors Play Useful Roles in Predicting Rich Coronary Collaterals in Patients with Coronary Heart Disease , 2010, The Journal of international medical research.

[20]  C. Peters,et al.  Impaired turnover of autophagolysosomes in cathepsin L deficiency , 2010, Biological chemistry.

[21]  Ajit P Yoganathan,et al.  Elevated cyclic stretch induces aortic valve calcification in a bone morphogenic protein-dependent manner. , 2010, The American journal of pathology.

[22]  A. Shukla,et al.  Cathepsins B and L in peripheral blood mononuclear cells of pediatric acute myeloid leukemia: potential poor prognostic markers , 2010, Annals of Hematology.

[23]  K. Okumura,et al.  AT1 blockade attenuates atherosclerotic plaque destabilization accompanied by the suppression of cathepsin S activity in apoE-deficient mice. , 2010, Atherosclerosis.

[24]  Peter P. Liu,et al.  Early detection of myocardial dysfunction and heart failure , 2010, Nature Reviews Cardiology.

[25]  Kwangmeyung Kim,et al.  Protease Imaging of Human Atheromata Captures Molecular Information of Atherosclerosis, Complementing Anatomic Imaging , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[26]  C. Peters,et al.  Cathepsin L inactivates human trypsinogen, whereas cathepsin L-deletion reduces the severity of pancreatitis in mice. , 2010, Gastroenterology.

[27]  L. Duong,et al.  Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double‐Blind, Randomized, Placebo‐Controlled Phase I Studies , 2009, Clinical pharmacology and therapeutics.

[28]  K. Okumura,et al.  Mechanism of Diastolic Stiffening of the Failing Myocardium and Its Prevention by Angiotensin Receptor and Calcium Channel Blockers , 2009, Journal of cardiovascular pharmacology.

[29]  A. Newman,et al.  Cystatin C associates with arterial stiffness in older adults. , 2009, Journal of the American Society of Nephrology : JASN.

[30]  P. Libby,et al.  Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease , 2009, Circulation.

[31]  T. Lindahl,et al.  Cystatin C and NT‐proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10‐year study in primary care , 2009, European journal of heart failure.

[32]  Ajit P Yoganathan,et al.  Elevated cyclic stretch alters matrix remodeling in aortic valve cusps: implications for degenerative aortic valve disease. , 2009, American journal of physiology. Heart and circulatory physiology.

[33]  Michael C. Ostrowski,et al.  Free Cholesterol Accumulation in Macrophage Membranes Activates Toll-Like Receptors and p38 Mitogen-Activated Protein Kinase and Induces Cathepsin K , 2009, Circulation research.

[34]  G. Shi,et al.  Usefulness of serum cathepsin L as an independent biomarker in patients with coronary heart disease. , 2009, The American journal of cardiology.

[35]  A. Khera,et al.  Association of Cystatin C With Left Ventricular Structure and Function: The Dallas Heart Study , 2009, Circulation. Heart failure.

[36]  L. Jonasson,et al.  Cathepsin L is significantly associated with apoptosis and plaque destabilization in human atherosclerosis. , 2009, Atherosclerosis.

[37]  Q. Tang,et al.  Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3β signaling , 2009, Journal of Molecular Medicine.

[38]  C. Peters,et al.  Major Role of Cathepsin L for Producing the Peptide Hormones ACTH, β-Endorphin, and α-MSH, Illustrated by Protease Gene Knockout and Expression* , 2008, Journal of Biological Chemistry.

[39]  K. Clément,et al.  Deficiency and Inhibition of Cathepsin K Reduce Body Weight Gain and Increase Glucose Metabolism in Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[40]  Vasilis Ntziachristos,et al.  Real-Time Catheter Molecular Sensing of Inflammation in Proteolytically Active Atherosclerosis , 2008, Circulation.

[41]  Benjamin A. Garcia,et al.  Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell Differentiation , 2008, Cell.

[42]  Stefanie Dimmeler,et al.  Homing and engraftment of progenitor cells: a prerequisite for cell therapy. , 2008, Journal of molecular and cellular cardiology.

[43]  H. Lee,et al.  Serum Cystatin C Is Related to Pulse Wave Velocity Even in Subjects with Normal Serum Creatinine , 2008, Hypertension Research.

[44]  A. Zeiher,et al.  High glucose reduces cathepsin L activity and impairs invasion of circulating progenitor cells. , 2008, Journal of molecular and cellular cardiology.

[45]  Kwanghee Kim,et al.  The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A , 2008, Nature Medicine.

[46]  H. Izawa,et al.  Cardiovascular , Pulmonary and Renal Pathology Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment , 2010 .

[47]  G. Salvesen,et al.  Cysteine Cathepsins Trigger Caspase-dependent Cell Death through Cleavage of Bid and Antiapoptotic Bcl-2 Homologues* , 2008, Journal of Biological Chemistry.

[48]  K. Miyazono,et al.  Cathepsin K-Dependent Toll-Like Receptor 9 Signaling Revealed in Experimental Arthritis , 2008, Science.

[49]  K. Brix,et al.  Cysteine cathepsins: cellular roadmap to different functions. , 2008, Biochimie.

[50]  S. Stoch,et al.  Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy , 2008, Clinical pharmacology and therapeutics.

[51]  O. Vasiljeva,et al.  Cell Type-specific Functions of the Lysosomal Protease Cathepsin L in the Heart* , 2007, Journal of Biological Chemistry.

[52]  P. Kovanen,et al.  Aortic valve stenosis: an active atheroinflammatory process , 2007, Current opinion in lipidology.

[53]  M. Daemen,et al.  Cathepsin cysteine proteases in cardiovascular disease , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  M. Linton,et al.  Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques. , 2007, Journal of the American Society of Nephrology : JASN.

[55]  A. Rudensky,et al.  Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. , 2007, The Journal of clinical investigation.

[56]  K. Clément,et al.  Cathepsin L activity controls adipogenesis and glucose tolerance , 2007, Nature Cell Biology.

[57]  Ralph Weissleder,et al.  Optical Visualization of Cathepsin K Activity in Atherosclerosis With a Novel, Protease-Activatable Fluorescence Sensor , 2007, Circulation.

[58]  Shin‐Rong Hwang,et al.  Cathepsin L Expression Is Directed to Secretory Vesicles for Enkephalin Neuropeptide Biosynthesis and Secretion* , 2007, Journal of Biological Chemistry.

[59]  K. Okumura,et al.  Mechanisms Underlying the Impairment of Ischemia-Induced Neovascularization in Matrix Metalloproteinase 2–Deficient Mice , 2007, Circulation research.

[60]  W. Stark,et al.  Interaction between Human Cathepsins K, L, and S and Elastins , 2007, Journal of Biological Chemistry.

[61]  H. Izawa,et al.  Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure , 2006, Hypertension.

[62]  Karine Clément,et al.  Cathepsin s promotes human preadipocyte differentiation: possible involvement of fibronectin degradation. , 2006, Endocrinology.

[63]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[64]  Vasilis Ntziachristos,et al.  Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo , 2006, Circulation.

[65]  Chengcheng Hu,et al.  Increased serum cathepsin S in patients with atherosclerosis and diabetes. , 2006, Atherosclerosis.

[66]  C. Peters,et al.  Lysosomal, cytoskeletal, and metabolic alterations in cardiomyopathy of cathepsin L knockout mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  Gang Zhao,et al.  Enhanced myocardial cathepsin B expression in patients with dilated cardiomyopathy , 2006, European journal of heart failure.

[68]  P. Quax,et al.  Pericellular proteases in angiogenesis and vasculogenesis. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[69]  K. Clément,et al.  Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. , 2006, The Journal of clinical endocrinology and metabolism.

[70]  T. Murohara,et al.  Localization of Cysteine Protease, Cathepsin S, to the Surface of Vascular Smooth Muscle Cells by Association with Integrin ανβ3 , 2006 .

[71]  P. Libby,et al.  Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells. , 2006, Atherosclerosis.

[72]  I. van der Made,et al.  Disruption of the Cathepsin K Gene Reduces Atherosclerosis Progression and Induces Plaque Fibrosis but Accelerates Macrophage Foam Cell Formation , 2005, Circulation.

[73]  T. Murohara,et al.  Localization of cysteine protease, cathepsin S, to the surface of vascular smooth muscle cells by association with integrin alphanubeta3. , 2006, The American journal of pathology.

[74]  M. Mäyränpää,et al.  Increased expression of elastolytic cathepsins S, K, and V and their inhibitor cystatin C in stenotic aortic valves. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[75]  Shotai Kobayashi,et al.  Neuronal cell death induced by cystatin C in vivo and in cultured human CNS neurons is inhibited with cathepsin B , 2005, Brain Research.

[76]  I. Kubota,et al.  Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. , 2005, Journal of cardiac failure.

[77]  Lin Yan,et al.  Autophagy in chronically ischemic myocardium. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[78]  C. Peters,et al.  The lysosomal cysteine protease cathepsin L regulates keratinocyte proliferation by control of growth factor recycling , 2005, Journal of Cell Science.

[79]  E. Chavakis,et al.  Cathepsin L is required for endothelial progenitor cell–induced neovascularization , 2005, Nature Medicine.

[80]  B. Psaty,et al.  Cystatin-C and mortality in elderly persons with heart failure. , 2005, Journal of the American College of Cardiology.

[81]  Frederick J Schoen,et al.  Heart valve regeneration. , 2005, Advances in biochemical engineering/biotechnology.

[82]  G. Dubin,et al.  Proteinaceous cysteine protease inhibitors , 2005, Cellular and Molecular Life Sciences.

[83]  G. Csucs,et al.  Exon Skipping of Cathepsin B , 2004, Journal of Biological Chemistry.

[84]  M. Mäyränpää,et al.  Cysteine Protease Cathepsin F Is Expressed in Human Atherosclerotic Lesions, Is Secreted by Cultured Macrophages, and Modifies Low Density Lipoprotein Particles in Vitro* , 2004, Journal of Biological Chemistry.

[85]  P. Libby,et al.  Lysosomal Cysteine Proteases in Atherosclerosis , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[86]  A. M. Romanic,et al.  Cathepsin S expression is up-regulated following balloon angioplasty in the hypercholesterolemic rabbit. , 2004, Cardiovascular research.

[87]  Mario Plebani,et al.  Biochemistry and Clinical Role of Human Cystatin C , 2004, Critical reviews in clinical laboratory sciences.

[88]  P. Seth,et al.  Transcription of human cathepsin L mRNA species hCATL B from a novel alternative promoter in the first intron of its gene. , 2003, Gene.

[89]  M. Bogyo,et al.  Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[90]  P. Libby,et al.  Deficiency of the Cysteine Protease Cathepsin S Impairs Microvessel Growth , 2003, Circulation research.

[91]  Makoto Naito,et al.  Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. , 2003, The Journal of clinical investigation.

[92]  Sanford M. Simon,et al.  Membrane proximal lysosomes are the major vesicles responsible for calcium-dependent exocytosis in nonsecretory cells , 2002, The Journal of cell biology.

[93]  Hua Cai,et al.  Role of p47phox in Vascular Oxidative Stress and Hypertension Caused by Angiotensin II , 2002, Hypertension.

[94]  A. Hamsten,et al.  Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice. , 2002, The American journal of pathology.

[95]  G. Salvesen,et al.  Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. , 2002, Current pharmaceutical design.

[96]  S. S. Chauhan,et al.  Identification and characterization of a novel human cathepsin L splice variant. , 2002, Gene.

[97]  Vasilis Ntziachristos,et al.  In Vivo Imaging of Proteolytic Activity in Atherosclerosis , 2002, Circulation.

[98]  Hidde L. Ploegh,et al.  Neuronal loss and brain atrophy in mice lacking cathepsins B and L , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[99]  R. Mason,et al.  Evolution of placentally expressed cathepsins. , 2002, Biochemical and biophysical research communications.

[100]  Christoph Peters,et al.  Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[101]  S. Goldring,et al.  Comparison of cathepsins K and S expression within the rheumatoid and osteoarthritic synovium. , 2002, Arthritis and rheumatism.

[102]  R. Frade,et al.  Characterization of human cathepsin L promoter and identification of binding sites for NF-Y, Sp1 and Sp3 that are essential for its activity. , 2002, The Biochemical journal.

[103]  J. Kos,et al.  Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. , 2002, Advances in enzyme regulation.

[104]  P. Libby,et al.  Activated Interstitial Myofibroblasts Express Catabolic Enzymes and Mediate Matrix Remodeling in Myxomatous Heart Valves , 2001, Circulation.

[105]  D. Turk,et al.  Lysosomal cysteine proteases: facts and opportunities , 2001, The EMBO journal.

[106]  E. Caler,et al.  Plasma Membrane Repair Is Mediated by Ca2+-Regulated Exocytosis of Lysosomes , 2001, Cell.

[107]  J. Deussing,et al.  Towards Specific Functions of Lysosomal Cysteine Peptidases: Phenotypes of Mice Deficient for Cathepsin B or Cathepsin L , 2001, Biological chemistry.

[108]  S. Weiss,et al.  Regulation of Elastinolytic Cysteine Proteinase Activity in Normal and Cathepsin K–Deficient Human Macrophages , 2000, The Journal of experimental medicine.

[109]  K. Hillan,et al.  Application of cDNA microarrays in determining molecular phenotype in cardiac growth, development, and response to injury. , 2000, Circulation.

[110]  H. Ploegh,et al.  Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages , 2000, The Journal of experimental medicine.

[111]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[112]  D. Turk,et al.  Lysosomal cysteine proteases: more than scavengers. , 2000, Biochimica et biophysica acta.

[113]  Bonnie F. Sloane,et al.  Transcription of human cathepsin B is mediated by Sp1 and Ets family factors in glioma. , 2000, DNA and cell biology.

[114]  P. Libby,et al.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms. , 1999, The Journal of clinical investigation.

[115]  K. Tao,et al.  Lysine-based Structure Responsible for Selective Mannose Phosphorylation of Cathepsin D and Cathepsin L Defines a Common Structural Motif for Lysosomal Enzyme Targeting* , 1998, The Journal of Biological Chemistry.

[116]  A. Baici,et al.  Inhibition of extracellular matrix-degrading endopeptidases: problems, comments, and hypotheses. , 1998, Biological chemistry.

[117]  P. Libby,et al.  Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.

[118]  J T Palmer,et al.  Crystal structure of human cathepsin S , 1998, Protein science : a publication of the Protein Society.

[119]  D. Turk,et al.  Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. , 1998, Structure.

[120]  D. Turk,et al.  Revised Definition of Substrate Binding Sites of Papain-Like Cysteine Proteases , 1998, Biological chemistry.

[121]  T. Ludwig,et al.  Differential Sorting of Lysosomal Enzymes Out of the Regulated Secretory Pathway in Pancreatic β-Cells , 1997, The Journal of cell biology.

[122]  D. Turk,et al.  Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. , 1997, Biological chemistry.

[123]  H. Chapman,et al.  Emerging roles for cysteine proteases in human biology. , 1997, Annual review of physiology.

[124]  R. Ménard,et al.  Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. , 1996, The EMBO journal.

[125]  R. Coulombe,et al.  Structure of rat procathepsin B: model for inhibition of cysteine protease activity by the proregion. , 1996, Structure.

[126]  S. Weiss,et al.  Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepsins B, L, and S, by human monocyte-derived macrophages. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[127]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[128]  J. Mort,et al.  Rat procathepsin B. Proteolytic processing to the mature form in vitro. , 1992, The Journal of biological chemistry.

[129]  C. Peters,et al.  Phylogenetic conservation of cysteine proteinases. Cloning and expression of a cDNA coding for human cathepsin S. , 1992, The Journal of biological chemistry.

[130]  D. Rich,et al.  Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. , 1992, The Journal of biological chemistry.

[131]  Robert Huber,et al.  The refined 2.15 A X‐ray crystal structure of human liver cathepsin B: the structural basis for its specificity. , 1991, The EMBO journal.

[132]  K. Kato,et al.  Inhibition of intracellular sorting and processing of lysosomal cathepsins H and L at reduced temperature in primary cultures of rat hepatocytes. , 1990, Archives of biochemistry and biophysics.

[133]  T. Tsukahara,et al.  Biosyntheses and processing of lysosomal cysteine proteinases in rat macrophages , 1988, FEBS letters.

[134]  K. Kato,et al.  Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. , 1988, Archives of biochemistry and biophysics.

[135]  H. Kresse,et al.  Biosynthesis of cathepsin B in cultured normal and I-cell fibroblasts. , 1987, The Journal of biological chemistry.

[136]  H. Neurath,et al.  Evolution of proteolytic enzymes. , 1984, Science.

[137]  R. Cannon,et al.  Role of cellular proteinases in acute myocardial infarction. I. Proteolysis in nonischemic and ischemic rat myocardium and the effects of antipain, leupeptin, pepstatin and chymostatin administered in vivo. , 1983, Journal of the American College of Cardiology.

[138]  K. Wildenthal,et al.  Changes in cardiac cathepsin B activity in response to interventions that alter heart size or protein metabolism: comparison with cathepsin D. , 1983, Journal of molecular and cellular cardiology.

[139]  Alan J. Barrett,et al.  [41] Cathepsin B, cathepsin H, and cathepsin L , 1981 .

[140]  A. Barrett,et al.  Cathepsin B, Cathepsin H, and cathepsin L. , 1981, Methods in enzymology.

[141]  J. Bonner,et al.  Differentiation , 1968, Nature.